Initial results from the study are expected in August
GlaxoSmithKline’s Covid-19 vaccine partnership with Clover Biopharmaceuticals started tests in humans, following a number of other programmes in the sprint to come up with a weapon to try to halt the pandemic.
Initial results from the study are expected in August, and a bigger efficacy trial is expected to start later in 2020, Glaxo said in a statement.
The University of Oxford, working with AstraZeneca, as well as Moderna and CanSino Biologics, are among the institutions and companies with programmes already in clinical trials as governments look for a way to slow the pandemic. An experimental COVID-19 vaccine from Imperial College London was starting tests in humans this week, relying on cutting-edge technology that scientists hope will allow hundreds of millions of doses to be produced quickly.
The Glaxo collaboration with Clover, Chinese biotech, relies on the UK company’s adjuvant system, a booster designed to enhance the body’s immune response. Glaxo has said it can reduce the amount of vaccine required per dose, allowing more people to be immunized, and create longer-lasting immunity.